{
  "abstract": "Objective: To assess the long-term oncologic and survival outcomes of percutaneous cryoablation (PCA) for patients with solitary de novo T1a renal cell carcinoma (RCC). Methods: This retrospective study was conducted following the STROBE guidelines. We included patients with a single, biopsy-confirmed, treatment-naïve T1a RCC (<4 cm) who underwent PCA between January 2008 and December 2021. Patient demographics, tumor characteristics, and procedural details were collected. Survival analyses were performed using the Kaplan–Meier estimator. Results: Eighty-six patients (57 men and 29 women) with a median age of 69 years met the inclusion criteria. Fifty patients (58%) had a history of an additional non-renal malignancy. In total, 86 renal tumors were treated using PCA, with a median tumor diameter of 2.7 cm. Clear cell RCC accounted for 67.4% of the tumors. Procedural complications classified as Clavien–Dindo grade III or higher occurred in 4.6% of cases. Local tumor recurrence at the ablation site was observed in five patients (5.8%), and four patients (4.6%) developed new lesions elsewhere within the kidney. The estimated median overall survival was 10.34 years. The 10-year local recurrence-free and disease-free survival rates were 93.5% and 84.0%, respectively. Both metastasis-free survival and cancer-specific survival rates at 10 years were 100%. Conclusions: Percutaneous cryoablation provided durable local tumor control with low major morbidity and favorable long-term oncologic outcomes in this selected cohort of patients with solitary cT1a renal tumors.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1471, Houston, TX 77030, USA",
    "Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA",
    "Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 14,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Mohamed E. Abdelsalam",
      "orcid": "0000-0003-1066-2641"
    },
    {
      "affs": [
        0
      ],
      "name": "Ahmed Awad"
    },
    {
      "affs": [
        0
      ],
      "name": "Robert J. Raymond"
    },
    {
      "affs": [
        1
      ],
      "name": "Zhongya Wang"
    },
    {
      "affs": [
        0
      ],
      "name": "David Irwin"
    },
    {
      "affs": [
        0
      ],
      "name": "Peiman Habibollahi"
    },
    {
      "affs": [
        0
      ],
      "name": "Zeyad A. Metwalli"
    },
    {
      "affs": [
        0
      ],
      "name": "Stephen R. Lee"
    },
    {
      "affs": [
        0
      ],
      "name": "Bruno C. Odisio",
      "orcid": "0000-0002-1771-8233"
    },
    {
      "affs": [
        0
      ],
      "name": "Thomas Lu"
    },
    {
      "affs": [
        2
      ],
      "name": "Brittney H. Cotta"
    },
    {
      "affs": [
        2
      ],
      "name": "Jose A. Karam"
    },
    {
      "affs": [
        2
      ],
      "name": "Surena F. Matin",
      "orcid": "0000-0003-1638-1445"
    },
    {
      "affs": [
        0
      ],
      "name": "Kamran Ahrar",
      "orcid": "0000-0002-7800-2300"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/ds2ydhs72jxet.bib",
  "cited_by": 0,
  "doi": "10.3390/cancers18203292",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702555/?tool=EBI",
  "id": "ds2ydhs72jxet",
  "issns": [
    "2072-6694"
  ],
  "landing_url": "https://www.mdpi.com/2072-6694/18/20/3292",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2740|Renal cell carcinoma treatment"
    ]
  ],
  "openalex": "W7221667030",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702555/pdf/?tool=EBI",
  "pmcid": "PMC13702555",
  "pmid": null,
  "published": "2026-10-01",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/ds2ydhs72jxet.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:58Z",
      "native_id": "10.3390/cancers18203292",
      "source": "crossref",
      "url": "https://www.mdpi.com/2072-6694/18/20/3292"
    },
    {
      "first_seen": "2026-10-30T12:21:45Z",
      "native_id": "PMC:PMC13702555",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13702555"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2072-6694",
      "subfield": "oncology"
    }
  ],
  "title": "Long-Term Outcomes of Cryoablation for Solitary De Novo T1a Renal Cell Carcinoma: A Tertiary Cancer Center Experience",
  "title_text": "Long-Term Outcomes of Cryoablation for Solitary De Novo T1a Renal Cell Carcinoma: A Tertiary Cancer Center Experience",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:21:45Z",
  "url": "https://research.draconitic.com/paper/ds2ydhs72jxet",
  "venue": "Cancers",
  "versions": []
}